Investigational therapy efzimfotase alfa shows promising Phase III results in rare bone disease

Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume

Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients

The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks

Bavarian Nordic seeks EMA nod for Mpox vaccine in children aged 2–11

The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN

Lupin receives FDA’s tentative approval for Sugammadex injection

Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery

GSK seeks European nod for promising Hepatitis B therapy

Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes

The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology

Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal

Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones

HDFC Bank, Smile Foundation launch 8 mobile medical units to serve 4 lakh in remote north India

The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities

New diabetes drug UBT251 shows strong phase 2 results in China

FDA nod to Johnson & Johnson’s oral psoriasis therapy 'ICOTYDE'

New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis